In recent years, thermotherapy has emerged as a promising approach in cancer care, offering potential to enhance treatment outcomes, reduce side effects, and improve patient quality of life when used alongside radiotherapy and chemotherapy. As clinical research continues to progress, the technology has drawn growing interest from medical institutions and investors. Sensius is one of the key innovators leading this field.
In June 2025, Sensius secured €15 million in funding to accelerate the clinical development and international rollout of its precision thermotherapy platform for cancer treatment. The round was co-led by UCEA Capital Partners and GrayBella Capital with EIC Fund from the European Innovation Council and a group of strategic investors.
Sensius, a spin-off from Erasmus University Medical Center in Rotterdam, is developing advanced precision thermotherapy systems to support standard cancer treatments such as radiotherapy and chemotherapy. The company’s technology allows targeted heat application to deep-seated tumors while protecting surrounding healthy tissue. Clinical use of the prototype system in head and neck cancer cases has already demonstrated promising results in both efficacy and patient well-being.
The new funding will support the launch of clinical trials across Europe and the United States. These trials are designed to validate the safety and effectiveness of Sensius’s platform and support the company’s regulatory and commercial efforts in key global markets.
UCEA Capital Partners continues to invest in early and growth-stage companies across healthcare, technology, energy and sports. The firm’s dedicated healthcare investment team focuses on supporting scalable, evidence-driven solutions that aim to deliver measurable improvements in human health. UCEA’s contribution to Sensius reflects this commitment, as well as its broader vision to support next-generation treatment platforms with global relevance.
Find out more at Sensius